Evidence map›Paper›PMID 38021091›Full record

ArticleClinical and translational radiation oncology2024

Comparative effectiveness of new treatment modalities for localized prostate cancer through patient-reported outcome measures.

Víctor Zamora, Olatz Garin, José Francisco Suárez, Cristina Gutiérrez, Ferran Guedea, Patricia Cabrera, Manuel Castells, Ismael Herruzo, Lluis Fumadó, Pilar Samper and 5 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Clinical and translational radiation oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05523856 (Comparative Effectiveness of New Treatment Modalities for Localized Prostate Cancer), which is not on this map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05523856 active not recruitingnot on this map

Comparative Effectiveness of New Treatment Modalities for Localized Prostate Cancer

TypeobservationalSponsorFundacion IMIMRan2014 to 2027Enrolled480ConditionsProstate CancerArmsActive Surveillance, Robot-Assisted Radical Prostatectomy, Intensity-Modulated Radiotherapy, Real-time brachytherapy
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. [Prostate cancer screening? Only evidence-based, risk-adjusted, and organized!]Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 10 institutions in 1 country.

Víctor ZamoraHealth Services Research Group, IMIM (Hospital del Mar Medical Research Institute) Barcelona, Spain.
Olatz GarinHealth Services Research Group, IMIM (Hospital del Mar Medical Research Institute) Barcelona, Spain.
José Francisco SuárezUrology Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
Cristina GutiérrezRadiation Oncology Department, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain.
Ferran GuedeaRadiation Oncology Department, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain.
Patricia CabreraRadiation Oncology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
Manuel CastellsUrology Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
Ismael HerruzoRadiation Oncology Department, Hospital Regional Universitario Carlos Haya, Málaga, Spain.
Lluis FumadóUrology Department, Hospital del Mar, Barcelona, Spain.
Pilar SamperRadiation Oncology Department, Hospital Universitario Rey Juan Carlos, Móstoles, Spain.
Carlos FerrerRadiation Oncology Department, Hospital Provincial de Castellón, Castellón, Spain.
Lucas RegisUrology Department, Hospital Universitario Vall d'Hebron, Barcelona, Spain.
Àngels PontHealth Services Research Group, IMIM (Hospital del Mar Medical Research Institute) Barcelona, Spain.
Montse FerrerHealth Services Research Group, IMIM (Hospital del Mar Medical Research Institute) Barcelona, Spain.
Multicentric Spanish Group of Clinically Localized Prostate Cancer
Bellvitge University Hospital · ESHospital Del Mar · ESInstitut Català d'Oncologia · ESUniversitat Pompeu Fabra · ESFundación Hospital Provincial de Castellón · ESHospital Regional Universitario de Málaga · ESHospital Universitario Rey Juan Carlos · ESHospital Universitario Virgen del Rocío · ESUniversitat Autònoma de Barcelona · ESVall d'Hebron Hospital Universitari · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: There is scarce comparative effectiveness research on the new treatment modalities for localized prostate cancer. We aim to compare through Patient-Reported Outcome Measures (PROMs) the impact of active surveillance, robot-assisted radical prostatectomy (RARP), intensity-modulated radiotherapy (IMRT), and real-time brachytherapy, considering side effects (incontinence, irritative/obstructive urinary symptoms, sexual dysfunction and bowel symptoms) and physical and mental health. Materials and Methods: Prospective cohort of men diagnosed with clinically localized prostate cancer (age 50-75y, T1-T2, and low risk including Gleason 3 + 4 in T1c) from 18 Spanish hospitals, followed up to 24 months. Treatment decisions were jointly made by patients and physicians (n = 572). The Expanded Prostate cancer Index Composite (EPIC-26) and Short-Form 36 (SF-36v2) were administered through telephone interviews before and three, six, 12, and 24 months after treatment. To account for correlation among repeated measures, generalized estimating equation models were constructed. All analyses were performed with propensity score weights to solve treatment selection bias. Results: The PROMs completion rate at 24 months was 95.0 %. Active surveillance entails the fewest side effects, but with significant sexual (0.4 standard deviations [SD], p < 0.001) and physical health deterioration (0.5 SD, p < 0.001); and moderate mental health improvement (0.4 SD, p = 0.001) at 24 months. Compared with active surveillance, RARP presented greater urinary incontinence (p = 0.030), and IMRT and real-time brachytherapy worse bowel symptoms (p = 0.027 and p = 0.007) at 24 months. Conclusions: Most side effects of the new treatment modalities seem to be limited to short-term deteriorations, except for moderate-large urinary incontinence in patients who had undergone RARP and moderate bowel deterioration in patients treated with IMRT or with real-time brachytherapy. Furthermore, patients under active surveillance, IMRT, and real-time brachytherapy showed a moderate improvement in mental health.

Indexed as

Active surveillanceComparative effectivenessIMRTLocalized prostate cancerPatient-reported outcome measuresReal-time brachytherapyRobot-assisted radical prostatectomy

Identifiers

PMID38021091
PMCPMC10663757
OpenAlexW4388160790

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.